Friday, July 10, 2026

pharma · Metastatic castration-resistant prostate cancer. · short-term treatment of insomnia

Orion Laboratories Pty

Orion Laboratories is a pharma organization headquartered in Baton Rouge, USA. Primary therapeutic focus areas include Metastatic castration-resistant prostate cancer., short-term treatment of insomnia, Parkinson desease

Baton Rouge, USA HQ
2008 Founded
52 Employees
TGA registrant Type
Company details
Status
Public
HQ
Baton Rouge, USA
Founded
2008
Employees
52
Programs
9
Drugs
20
Patents
0
Clinical program

3133003

Phase 2 · small molecule · Chronic Pain due to Ostheoarthritis of the knee

3133003 for Chronic Pain due to Ostheoarthritis of the knee is a Phase 2 program (small_molecule) at Orion Laboratories Pty. with 1 ClinicalTrials.gov record(s).

← All Orion Laboratories Pty. projects Phase 2 small molecule active

Internal code 3133003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Orion Laboratories Pty.
Phase
Phase 2
Modality
small_molecule
Indication
Chronic Pain due to Ostheoarthritis of the knee
Status
active
Trials
1